Document is current
Any future updates will be listed below
-
Authors
Klusek, Jessica https://orcid.org/0000-0002-2818-0344
Fairchild, Amanda
Moser, Carly
Mailick, Marsha R.
Thurman, Angela John
Abbeduto, Leonard
-
Funding
Funding for this research was provided by:
National Institutes of Health (R03HD098291, R21DC017804, F32DC013934, R01HD024356, P50HD103526, P50HD103573)
- License Information
-
More Information
Article History
Received: 30 April 2021
Accepted: 2 January 2022
First Online: 14 January 2022
Declarations
:
: LA has received funding to develop and implement outcome measures for clinical trials from F. Hoffman-LaRoche, Ltd., Roche TCRC, Inc., Neuren Pharmaceuticals Limited, Inc, and the LuMind IDSC Foundation. AJT has received funding to develop and implement outcome measures from Fulcrum Therapeutic. MM serves as the chair of the Scientific Advisory Board of the John Merck Fund Developmental Disabilities Program. The authors have no other relevant conflicts of interest to disclose.
